A prior study has demonstrated that combining a peptide tumor vaccine (gp100) with HDIL-2 can improve the response rates and prolong overall survival (OS) compared to HDIL-2 monotherapy by priming the immune system to tumor-specific antigens [11]. Here, PMEL is linked to neoplasm.